Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate

The BCL2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. In acute myeloid leukemia (AML), venetoclax combined with hypomethylating agents is the standard of care for patients unfit for intensive chemotherapy, but intrinsic and acquired resistance are common. Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in TP53-mutant AML. Other frequent mechanisms of venetoclax resistance in AML include FLT3 mutations, MCL-1 upregulation, and altered mitochondrial metabolism. Unfortunately, it has been challenging to develop agents that target these mechanisms directly and combinatorially. Here we report that pitavastatin, an inhibitor of HMG-CoA-reductase, promotes apoptosis and overcomes several venetoclax resistance mechanisms in human AML cells. At clinically achievable concentrations, pitavastatin treatment has potent cytotoxic activity in cells with mutations in TP53 or FLT3. The apoptotic mechanism involves p53-independent PUMA upregulation and reduced MCL-1 expression. Pitavastatin also suppresses mitochondrial gene expression and oxidative metabolism. The pro-apoptotic actions of pitavastatin depend on depletion of geranylgeranyl pyrophosphate (GGPP) and can be recapitulated by inhibiting GGPP synthase or geranylgeranyltransferase-1 enzymes. These results provide a mechanistic rationale for adding pitavastatin to AML regimens to prevent or overcome venetoclax resistance.

• Publication year

  2025

• Venue

  bioRxiv

• Publication date

  2025-11-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1101/2025.10.27.684888PMID 41280002PMCID 12636571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response

  2025cited by this paper
• A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

  2024cited by this paper
• RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

  2024cited by this paper
• Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia

  2024cited by this paper
• A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy

  2024cited by this paper
• A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

  2024cited by this paper
• Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

  2024cited by this paper
• Statins as anti‐tumor agents: A paradigm for repurposed drugs

  2024cited by this paper
• Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer

  2024cited by this paper
• Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia.

  2023cited by this paper
• Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors

  2023cited by this paper
• Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress—CHOP pathway

  2023cited by this paper
• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

  2023cited by this paper
• Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

  2022cited by this paper
• Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

  2022cited by this paper
• AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.

  2022cited by this paper
• Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

  2021cited by this paper
• Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

  2021cited by this paper
• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

  2020cited by this paper
• Targeting the Mevalonate Pathway in Cancer.

  2020cited by this paper
• Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

  2020cited by this paper
• Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

  2020cited by this paper
• Statins as Anticancer Agents in the Era of Precision Medicine

  2020cited by this paper
• Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation

  2020cited by this paper
• Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

  2020cited by this paper
• Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

  2019cited by this paper
• The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

  2019cited by this paper
• Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response

  2019cited by this paper
• Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

  2019cited by this paper
• Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

  2018cited by this paper
• The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug repurposing.

  2018cited by this paper
• Statins enhance efficacy of venetoclax in blood cancers

  2018cited by this paper
• An inhibitor of oxidative phosphorylation exploits cancer vulnerability

  2018cited by this paper
• Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

  2018cited by this paper
• Will we be able to afford a cure in multiple myeloma?

  2018cited by this paper
• BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

  2018cited by this paper
• Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies

  2018cited by this paper
• The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery.

  2018cited by this paper
• AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

  2018cited by this paper
• Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

  2018cited by this paper
• Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

  2017cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice

  2016cited by this paper
• The interplay between cell signalling and the mevalonate pathway in cancer

  2016cited by this paper
• Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport

  2016cited by this paper
• Targeting BCL-2-like Proteins to Kill Cancer Cells.

  2016cited by this paper
• Protein prenylation: unique fats make their mark on biology

  2016cited by this paper
• Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma

  2015cited by this paper
• Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.

  2014cited by this paper
• Targeting tumor cell metabolism with statins

  2012cited by this paper
• Pitavastatin - pharmacological profile from early phase studies.

  2010cited by this paper
• Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma

  2007cited by this paper
• Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I.

  2006cited by this paper
• Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.

  2005cited by this paper
• Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.

  2003cited by this paper
• Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

  2001cited by this paper
• A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors

  2001cited by this paper
• Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin.

  1994cited by this paper

• No citing papers are available for this paper.